Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

of additional higher doses of LX2931 as an orally-delivered treatment for rheumatoid arthritis," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "While we were disappointed by the unusually high placebo effect in this trial, we are encouraged by the excellent overall safety profile observed in the first test of this new mechanism of action in patients with RA."  

The company intends to commence discussions with potential pharmaceutical partners to pursue further development of LX2931 in rheumatoid arthritis.

Clinical Trial

The recently completed study was a 12-week, randomized, double-blind, placebo-controlled study in 208 patients on stable dose methotrexate with progressing rheumatoid arthritis. Patients were randomized to receive either placebo (n=49) or LX2931, 70 mg (n=55), 110 mg (n=54), or 150 mg (n=50), once daily for 12 weeks.  In addition to measurements to assess the drug's safety, efficacy endpoints included the primary endpoint, ACR20 at week 12, as well as secondary endpoints of ACR20, ACR50, ACR70 and DAS28 at weeks 4, 8 and 12.  The trial was conducted at sites within the United States and Eastern Europe.

About S1P Lyase and the Role of S1P in Autoimmune Disease

S1P lyase is responsible for the irreversible degradation of S1P, a biologically active lipid that can act as a second messenger in signal transduction pathways important for immune function.  Changes in local S1P concentrations and gradients in immune tissues can modify lymphocyte migration, inflammatory cell response, and affect barrier function of endothelial cells.  Inhibiting S1P lyase results in an increase in S1P levels, primarily in lymphoid tissues.  The physiological outcome of raising S1P levels in the lymphoid system is immune-modulation, which offers new opportunities for treating autoimmune and inflammatory
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
(Date:5/29/2015)... ON , May 29, 2015 /CNW/ - Covalon ... an advanced medical technologies company, is delighted to ... ended March 31, 2015, which includes revenue for ... the quarter of $264,340. Revenue from advanced wound care ... March 31, 2015 increased 24% to $1,742,672 compared ...
(Date:5/29/2015)... May 29, 2015  Epic Sciences announced today that ... from metastatic castrate resistant prostate cancer patients, at ... for Clinical Oncology. This application expands the investigational ... behind™ platform to characterize circulating tumor cell ... stage patients have heterogeneous clonal CTC populations harboring ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3
(Date:5/30/2015)... 2015 The iconic American actor, and ... hosting a new segment on Medical Malpractice. This segment ... malpractice in the health care field. , According to ... medical malpractice suits were filed, roughly only 20% of ... out of court, while the remaining 30% were tossed ...
(Date:5/30/2015)... “ Milli the Snail ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... engages and educates children. , Interactive mobile games for children ... content and games they are playing are doing much for ...
(Date:5/30/2015)... Nevada (PRWEB) May 30, 2015 Venus ... of acne scars, large pores, deep wrinkles, stretch marks, ... licensed medical professional, such as Dr. F. Victor Rueckl ... of the clinical trials in Las Vegas. This body ... technology into a system that delivers proven results through ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 Displays and ... that has lowered the price of hanging signs ; ... Hanging signs that hang down from ceiling rigging points at ... over the trade show floor. These signs are very ... there are additional costs for installation and dismantle labor and ...
(Date:5/29/2015)... May 29, 2015 Based in St. Louis, ... awareness shirts for a couple of months now and ... latest release, which reads “I’m not misbehaving, I have Autism, ... the parent’s of an autistic child in order to start ... , Not only are they raising awareness through the autism ...
Breaking Medicine News(10 mins):Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2
... uninsured accounted for almost 1 out of 5 ... -- An estimated 50 million, or 42 percent, of ... hospital emergency departments were billed to the Medicaid and ... Thursday. , Uninsured patients accounted for nearly 18 percent ...
... , , ABA program will ... CALDWELL, N.J., July 31 Caldwell College will launch the ... (ABA), a well developed scientific discipline that is best known for ... Caldwell,s program was recently approved by the New Jersey Commission ...
... July 31 /PRNewswire-FirstCall/ - Hard to Treat Diseases,Inc. (HTDS:PK), ... MEVAC-DTaP (Diphtheria, Tetanus and Acellular,Pertussis Combined Vaccine, adsorbed) had ... The sample analysis is expected to be completed,within the ... Terry Yuan CEO of HTDS said (sic) "We welcome ...
... 31 As the world prepares for a probable ... Pittsburgh researchers are controlling the spread of infectious diseases ... (NIH) grant to establish a Center of Excellence in ... the NIH,s Modeling of Infectious Disease Agent Study (MIDAS) ...
... July 31, 2009 Raytheon Company (NYSE: RTN ... public health-led team of first responders and hospital personnel in ... information. , , The EPTS, ... of victims during mass casualty incidents by providing selected patient ...
... expect meds to relieve stress, personal troubles, researchers caution, ... growing number of Americans now have a positive opinion ... About five out of six people surveyed felt psychiatric ... also expected the medications could help people deal with ...
Cached Medicine News:Health News:ER Visits Mostly by Medicare, Medicaid Recipients 2Health News:Caldwell College Receives Approval to Launch First Ph.D. for Applied Behavior Analysis-Autism Treatment in New Jersey 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 3Health News:Pitt receives $13.4 million NIH grant to create virtual models for epidemics 2Health News:Raytheon to Provide California First Responders and Healthcare Personnel Electronic Patient Tracking System 2Health News:Psych Drugs Gaining Widespread Acceptance 2Health News:Psych Drugs Gaining Widespread Acceptance 3
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard angled tying forceps made of titanium has angled 45 shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 102 mm....
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
McPherson angled tying forceps made of titanium tying forceps, angled 45 shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 84 mm....
Medicine Products: